[
  {
    "patient_id": "PATIENT_CPIC_6GENE",
    "drug": "Codeine",
    "timestamp": "2026-02-20T10:00:00.000000",
    "risk_assessment": {
      "risk_label": "Adjust Dosage",
      "confidence_score": 0.95,
      "severity": "moderate"
    },
    "cpic_guidelines": {
      "recommendation_level": "2A",
      "strength_of_recommendation": "Strong",
      "clinical_guidance": "Intermediate metabolizers have reduced morphine formation (10-20% reduction). Consider higher doses or shorter intervals.",
      "cpic_evidence": "2A - Moderate",
      "reference": "CPIC Codeine/CYP2D6 Guideline v2.1"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2D6",
      "diplotype": "*1/*2",
      "phenotype": "Intermediate Metabolizer",
      "detected_variants": [
        {
          "rsid": "rs3892097",
          "gene": "CYP2D6",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer (IM)"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Consider higher than normal dose or shorter dosing intervals; pain response-driven titration",
      "dosing": "120-150% of standard dose may be needed",
      "monitoring": "Assess pain control; titrate dose based on response (may need 30-60 mg per dose)"
    },
    "llm_generated_explanation": {
      "summary": "CYP2D6 IM phenotype suggests reduced codeine-to-morphine conversion",
      "clinical_impact": "CYP2D6 (IM): Adjust dosage - 20% increased analgesic requirements"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": ["CYP2D6", "CYP2C9", "CYP2C19", "TPMT", "SLCO1B1", "DPYD"],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2.1"
    }
  },
  {
    "patient_id": "PATIENT_CPIC_6GENE",
    "drug": "Warfarin",
    "timestamp": "2026-02-20T10:00:00.000000",
    "risk_assessment": {
      "risk_label": "Adjust Dosage",
      "confidence_score": 0.95,
      "severity": "moderate"
    },
    "cpic_guidelines": {
      "recommendation_level": "1A",
      "strength_of_recommendation": "Strong",
      "clinical_guidance": "CYP2C9 *1/*2 (Intermediate metabolizer): 5-7 mg/day initial dose. VKORC1 not available in this test profile.",
      "cpic_evidence": "1A - Strong",
      "reference": "CPIC Warfarin/CYP2C9/VKORC1 Guideline v2.0"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2C9",
      "diplotype": "*1/*2",
      "phenotype": "Intermediate Metabolizer",
      "detected_variants": [
        {
          "rsid": "rs1057910",
          "gene": "CYP2C9",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer (IM)"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Reduce initial dose to 5-7 mg daily; adjust based on INR response. More frequent INR monitoring required.",
      "dosing": "50-70% of standard dose (5-7 mg initial)",
      "monitoring": "INR at baseline, 2-7 days, weekly x 1-2 weeks, then every 1-4 weeks. Target INR 2.0-3.0"
    },
    "llm_generated_explanation": {
      "summary": "CYP2C9 IM phenotype strongly predicts reduced warfarin metabolism",
      "clinical_impact": "CYP2C9 (IM): Reduce dose 30-40% | Higher sensitivity to warfarin"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": ["CYP2D6", "CYP2C9", "CYP2C19", "TPMT", "SLCO1B1", "DPYD"],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2.0"
    }
  },
  {
    "patient_id": "PATIENT_CPIC_6GENE",
    "drug": "Clopidogrel",
    "timestamp": "2026-02-20T10:00:00.000000",
    "risk_assessment": {
      "risk_label": "Adjust Dosage",
      "confidence_score": 0.95,
      "severity": "moderate"
    },
    "cpic_guidelines": {
      "recommendation_level": "2B",
      "strength_of_recommendation": "Moderate",
      "clinical_guidance": "CYP2C19 *1/*2 (Intermediate metabolizer): Reduced antiplatelet effect; may not achieve therapeutic levels.",
      "cpic_evidence": "2B - Moderate",
      "reference": "CPIC Clopidogrel/CYP2C19 Guideline v3.0"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "CYP2C19",
      "diplotype": "*1/*2",
      "phenotype": "Intermediate Metabolizer",
      "detected_variants": [
        {
          "rsid": "rs4244285",
          "gene": "CYP2C19",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Metabolizer (IM)"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Consider alternative antiplatelet (prasugrel 5-10 mg or ticagrelor 60-90 mg) OR increase clopidogrel dose",
      "dosing": "Increase to 600 mg loading dose, 150 mg daily maintenance (vs standard 300/75 mg)",
      "monitoring": "Heightened risk for stent thrombosis; assess response; consider platelet function testing"
    },
    "llm_generated_explanation": {
      "summary": "CYP2C19 IM phenotype results in suboptimal clopidogrel activation",
      "clinical_impact": "CYP2C19 (IM): Reduced antiplatelet effect - alternative P2Y12 inhibitor preferred"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": ["CYP2D6", "CYP2C9", "CYP2C19", "TPMT", "SLCO1B1", "DPYD"],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v3.0"
    }
  },
  {
    "patient_id": "PATIENT_CPIC_6GENE",
    "drug": "Simvastatin",
    "timestamp": "2026-02-20T10:00:00.000000",
    "risk_assessment": {
      "risk_label": "Increased Risk",
      "confidence_score": 0.90,
      "severity": "moderate"
    },
    "cpic_guidelines": {
      "recommendation_level": "2B",
      "strength_of_recommendation": "Moderate",
      "clinical_guidance": "SLCO1B1 *1/*2 (Decreased function): Increased simvastatin concentrations and myopathy risk. Reduce dose or use alternative.",
      "cpic_evidence": "2B - Moderate",
      "reference": "CPIC Simvastatin/SLCO1B1 Guideline v1.0"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "SLCO1B1",
      "diplotype": "*1/*2",
      "phenotype": "Decreased Function",
      "detected_variants": [
        {
          "rsid": "rs4149056",
          "gene": "SLCO1B1",
          "genotype": "*1/*2",
          "phenotype": "Decreased Function"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Reduce simvastatin dose to 5 mg daily maximum; consider pravastatin or rosuvastatin (not SLCO1B1 substrates)",
      "dosing": "5 mg daily (vs standard 10-40 mg range)",
      "monitoring": "Assess muscle symptoms (pain, weakness, dark urine); measure CK baseline; LFTs at baseline and 12 weeks"
    },
    "llm_generated_explanation": {
      "summary": "SLCO1B1 decreased function impairs simvastatin hepatic uptake",
      "clinical_impact": "SLCO1B1 (*1/*2): 4-fold increased simvastatin levels - myopathy and rhabdomyolysis risk"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": ["CYP2D6", "CYP2C9", "CYP2C19", "TPMT", "SLCO1B1", "DPYD"],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v1.0"
    }
  },
  {
    "patient_id": "PATIENT_CPIC_6GENE",
    "drug": "Azathioprine",
    "timestamp": "2026-02-20T10:00:00.000000",
    "risk_assessment": {
      "risk_label": "Adjust Dosage",
      "confidence_score": 0.95,
      "severity": "moderate"
    },
    "cpic_guidelines": {
      "recommendation_level": "1A",
      "strength_of_recommendation": "Strong",
      "clinical_guidance": "TPMT *1/*2 (Intermediate activity): Increased risk of 6-TGN accumulation and bone marrow toxicity. Reduce dose 25-50%.",
      "cpic_evidence": "1A - Strong",
      "reference": "CPIC Azathioprine/TPMT Guideline v2.1"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "TPMT",
      "diplotype": "*1/*2",
      "phenotype": "Intermediate Metabolizer",
      "detected_variants": [
        {
          "rsid": "rs1800462",
          "gene": "TPMT",
          "genotype": "*1/*2",
          "phenotype": "Intermediate Activity"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Reduce standard azathioprine dose by 25-50%; start with 0.5-1 mg/kg/day (vs 1-2.5 mg/kg standard)",
      "dosing": "50% dose reduction (e.g., 25 mg daily instead of 50 mg)",
      "monitoring": "CBC (white blood cell count, hemoglobin, platelets) weekly x 4-6 weeks, then every 2 weeks. Watch for infections, anemia, bleeding"
    },
    "llm_generated_explanation": {
      "summary": "TPMT intermediate activity leads to increased 6-TGN metabolite accumulation",
      "clinical_impact": "TPMT (IM): Bone marrow toxicity risk - mandatory dose reduction"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": ["CYP2D6", "CYP2C9", "CYP2C19", "TPMT", "SLCO1B1", "DPYD"],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v2.1"
    }
  },
  {
    "patient_id": "PATIENT_CPIC_6GENE",
    "drug": "Fluorouracil",
    "timestamp": "2026-02-20T10:00:00.000000",
    "risk_assessment": {
      "risk_label": "Adjust Dosage",
      "confidence_score": 0.95,
      "severity": "moderate"
    },
    "cpic_guidelines": {
      "recommendation_level": "2A",
      "strength_of_recommendation": "Moderate",
      "clinical_guidance": "DPYD *1/*2 (Decreased activity): Reduced fluorouracil clearance; significantly increased toxicity risk (neutropenia, mucositis, diarrhea).",
      "cpic_evidence": "2A - Moderate",
      "reference": "CPIC Fluorouracil/DPYD Guideline v1.0"
    },
    "pharmacogenomic_profile": {
      "primary_gene": "DPYD",
      "diplotype": "*1/*2",
      "phenotype": "Decreased Activity",
      "detected_variants": [
        {
          "rsid": "rs3918290",
          "gene": "DPYD",
          "genotype": "*1/*2",
          "phenotype": "Decreased Activity"
        }
      ]
    },
    "clinical_recommendation": {
      "summary": "Reduce fluorouracil dose by 25-50%; start with lower dose and titrate slowly based on tolerance",
      "dosing": "50% dose reduction (e.g., 500 mg/m² instead of 1000 mg/m² daily)",
      "monitoring": "Frequent CBC monitoring; watch closely for severe neutropenia, mucositis grade 3+, diarrhea. Consider alternative chemotherapy if severe toxicity"
    },
    "llm_generated_explanation": {
      "summary": "DPYD decreased activity impairs fluorouracil metabolism and clearance",
      "clinical_impact": "DPYD (*1/*2): Severe toxicity risk - mandatory dose reduction and intensive monitoring"
    },
    "quality_metrics": {
      "vcf_parsing_success": true,
      "genes_analyzed": ["CYP2D6", "CYP2C9", "CYP2C19", "TPMT", "SLCO1B1", "DPYD"],
      "variant_count": 6,
      "data_completeness": "standard",
      "algorithm_version": "CPIC-aligned-v1.0"
    }
  }
]
